COMP <GO>
DERM vs UNH // OPERATING MARGIN
Journey Medical Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: DERM 1
— UNH 10
▲ OPERATING MARGIN LEADER: UNH
LAST: $4.79 (-7.35%) • MKT CAP: $145.9M
operating-margins
-13.30%
LAST: $400.44 (-1.60%) • MKT CAP: $365.29B
operating-margins
4.82%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DERM | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.80% | 88.57% | -22.77 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -19.50% | 11.47% | -30.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.15% | 6.47% | -14.62 | UNH | /fcf-yield <GO> |
| Operating Margin ACTIVE | -13.30% | 4.82% | -18.12 | UNH | /operating-margins <GO> |
| Net Profit Margin | -18.70% | 3.14% | -21.84 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 11.10% | 6.46% | +4.64 | DERM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.74 | 3.12 | -2.38 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 57.4 | -16.90 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $145.9M | $365.29B | -$365.15B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DERM REV | UNH REV | DERM GROSS % | UNH GROSS % | DERM FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.2M | $447.57B | 65.8% | 88.7% | -$12.4M | $16.07B |
| FY 2024 | $55.1M | $400.28B | 62.1% | 88.3% | -$9.1M | $20.70B |
| FY 2023 | $59.7M | $371.62B | — | 89.6% | $5.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
UNH // BETA 0.33